CA
NZ
UK
AU
IND
US
● Evofem Biosciences occupies a difficult corner of the women's-health market: a company with genuine, FDA-cleared products but a share price measured in fractions of a cent.
● The roughly 1.1% decline on September 9, 2026 has no single, verifiable public catalyst; at this price and market size, small moves are ordinary.
● The attention is tied to Ernexa positioning itself as an approaching clinical-stage company rather than to any single verifiable same-day event.
● Emeryville, California-based Estrella Immunopharma develops engineered T-cell therapies for blood cancers, led by EB103, a CD19-directed candidate built on its ARTEMIS T-cell receptor platform.
The ticker EAPH (OTC:EAPH) has indeed gone quiet, and in more ways than a flatTrading sessionsuggests. The symbol once belonged to Easton Pharmaceuticals Inc., a Toronto-based company that has since rebranded to Parallel Industries Inc. and, by available accounts, no longer conducts significant operations. …
eHouse Global (OTC:EHOS) is a reminder that not every ticker on a screener belongs to a living, reporting company. The stock trades at a fraction of a cent, and the entity behind it stopped filing with the U.S. Securities and Exchange Commission roughly a …
Elite Pharmaceuticals has quietly become one of the more striking turnaround stories in the generic-drug business, yet its shares have drifted lower even as the company posts record numbers. The pullback in Elite Pharmaceuticals, Inc (OTCQB: ELTP) stock stands in sharp contrast to a …
Elicio Therapeutics has spent 2026 navigating one of the hardest stretches a clinical-stage biotech can face: a lead trial that missed its primary goal, followed by the difficult work of resetting its strategy. Against that backdrop, a single-day slide in Elicio Therapeutics, Inc (NASDAQ: …
A commercial-stage medical-device maker reshaping itself around a single regulatory catalyst, Elutia Inc. (NASDAQ: ELUT) has become a study in transition. The stock hovers near $0.80 with a market capitalization around $35 million after a steep year-long decline, and September finds investors weighing a …
Few 2022-era spin-offs have travelled a rockier road than Embecta Corp (NASDAQ: EMBC), the diabetes-care company carved out of Becton, Dickinson. After a punishing 2026, another single-session slide has again put the maker of pen needles and syringes in focus. The move fits a …
Please wait processing your request...